Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining

被引:5
作者
Hashimoto, Takafumi [1 ]
Osoegawa, Atsushi [1 ]
Takumi, Yohei [1 ]
Abe, Miyuki [1 ]
Kobayashi, Ryoji [1 ]
Miyawaki, Michiyo [1 ]
Takeuchi, Hideya [1 ]
Okamoto, Tatsuro [1 ]
Sugio, Kenji [1 ]
机构
[1] Oita Univ, Fac Med, Dept Thorac & Breast Surg, 1-1 Idaigaoka,Hasama Machi, Yufu, Oita 8795593, Japan
关键词
Lung cancer; Intratumoral heterogeneity; Epidermal growth factor receptor; Immunohistochemistry; Copy number variation; MUTATION-SPECIFIC ANTIBODIES; ACQUIRED-RESISTANCE; EGFR MUTATION; 1ST-LINE TREATMENT; OPEN-LABEL; MESENCHYMAL TRANSITION; TUMOR HETEROGENEITY; GENETIC ALTERATIONS; EVOLUTION; GEFITINIB;
D O I
10.1016/j.lungcan.2018.08.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although intratumoral heterogeneity is commonly observed in several cancers, few studies have shown its presence in EGFR-mutated lung cancer. We performed immunohistochemistry to analyze the intratumoral heterogeneity in EGFR-mutated (L858R) lung cancer and performed targeted sequencing in specific cases. We discuss the effects of intratumoral heterogeneity and acquired resistance to EGFR-TKI. Methods: Twenty resected primary lung cancers known to harbor EGFR L858R were analyzed. IHC was performed using an L858R mutant-specific rabbit monoclonal antibody and the samples were scored by staining intensity (0-3) and proportion. For cases with heterogeneous L858R protein expression, the nucleic acids were extracted from each differently stained lesion, and targeted sequencing was performed. Single nucleotide variations (SNVs) and copy number variations (CNVs) were then analyzed. The cell proliferation and apoptosis were also evaluated by the ki-67 labeling index and TUNEL staining. Results: Among 20 cases, 3 showed heterogeneous staining. Genetic analyses for cases with heterogeneous staining revealed an increase in the copy number of EGFR in the IHC-positive part compared to the negative part, and an increase in the copy number of CCNE1 was observed in the IHC-positive part compared to the negative part in one case (case 1). In another case (case 2), an increase in the copy number of EGFR was observed in the IHC-positive part compared to the negative part, and an increase in the copy number of MDM2 was observed in the IHC-positive part compared to the negative part. In three cases, no SNV changes were observed. An increase in the ki-67 labeling index in the L858R-positive part in case 1 and increased apoptosis in the L858R-positive part in case 2 were observed, suggesting the functional significance of CNV changes. Conclusion: These cases exhibiting L858R IHC intratumoral heterogeneity suggest a heterogeneous effect on the cell activity due to CNV heterogeneity.
引用
收藏
页码:241 / 247
页数:7
相关论文
共 50 条
  • [21] The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study
    You, Liangkun
    Zheng, Xinnan
    Deng, Danchen
    Pan, Hongming
    Han, Weidong
    [J]. SCIENTIFIC REPORTS, 2022, 12 (01)
  • [22] Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer
    Helio A. Costa
    Joel W. Neal
    Carlos D. Bustamante
    James L. Zehnder
    [J]. Molecular Diagnosis & Therapy, 2017, 21 : 431 - 436
  • [23] Identification of a Novel Somatic Mutation Leading to Allele Dropout for EGFR L858R Genotyping in Non-Small Cell Lung Cancer
    Costa, Helio A.
    Neal, Joel W.
    Bustamante, Carlos D.
    Zehnder, James L.
    [J]. MOLECULAR DIAGNOSIS & THERAPY, 2017, 21 (04) : 431 - 436
  • [24] Brain metastases in patients with non-small cell lung cancer: the role of mutated-EGFRs with an exon 19 deletion or L858R point mutation in cancer cell dissemination
    Hsiao, Shih-Hsin
    Chou, Yu-Ting
    Lin, Sey-En
    Hsu, Ru-Chun
    Chung, Chi-Li
    Kao, Yu-Rung
    Liu, H. Eugene
    Wu, Cheng-Wen
    [J]. ONCOTARGET, 2017, 8 (32) : 53405 - 53418
  • [25] EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation
    Xu, Jianlin
    Yang, Haitang
    Jin, Bo
    Lou, Yuqing
    Zhang, Yanwei
    Zhang, Xueyan
    Zhong, Hua
    Wang, Huiming
    Wu, Dan
    Han, Baohui
    [J]. SCIENTIFIC REPORTS, 2016, 6
  • [26] Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation
    Gilardone, Sophia
    Thapa, Ram
    Laborde, Jose
    Shafique, Michael
    Saltos, Andreas
    Creelan, Ben
    Tanvetyanon, Tawee
    Chiappori, Alberto
    Simon, George
    Haura, Eric B.
    Gray, Jhanelle E.
    Chen, Dung-Tsa
    Melzer, Daniel
    Pellini, Bruna
    [J]. JOURNAL OF THORACIC DISEASE, 2023, 15 (11) : 6115 - +
  • [27] Leptomeningeal Metastatic L858R EGFR-mutant Lung Cancer: Prompt Response to Osimertinib in the Absence of T790M-mutation and Effective Subsequent Pulsed Erlotinib
    Kanbour, Aladdin
    Salih, Faroug
    Abualainin, Wafa
    Abdelrazek, Mohamed
    Szabados, Lajos
    Al-Bozom, Issam
    Omar, Nabil E.
    [J]. ONCOTARGETS AND THERAPY, 2022, 15 : 659 - 667
  • [28] L858R emerges as a potential biomarker predicting response of lung cancer models to anti-EGFR antibodies: Comparison of osimertinib vs. cetuximab
    Marrocco, Ilaria
    Giri, Suvendu
    Simoni-Nieves, Arturo
    Gupta, Nitin
    Rudnitsky, Anna
    Haga, Yuya
    Romaniello, Donatella
    Sekar, Arunachalam
    Zerbib, Mirie
    Oren, Roni
    Lindzen, Moshit
    Fard, Damon
    Tsutsumi, Yasuo
    Lauriola, Mattia
    Tamagnone, Luca
    Yarden, Yosef
    [J]. CELL REPORTS MEDICINE, 2023, 4 (08)
  • [29] Wighteone exhibits an antitumor effect against EGFR L858R/T790M mutation non-small cell lung cancer
    Sun, Peiyuan
    Qu, Yana
    Wang, Yuna
    Wang, Jing
    Wang, Xuanjun
    Sheng, Jun
    [J]. JOURNAL OF CANCER, 2021, 12 (13): : 3900 - 3908
  • [30] Non-small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib
    Kunishige, Michihiro
    Ichihara, Seiya
    Kadota, Naoki
    Okano, Yoshio
    Machida, Hisanori
    Hatakeyama, Nobuo
    Naruse, Keishi
    Shinohara, Tsutomu
    Takeuchi, Eiji
    [J]. THORACIC CANCER, 2023, 14 (04) : 423 - 426